Price Alert

Alvotech (ALVO)

NASDAQ: ALVO · Real-Time Price · USD

8.47

-0.49 (-5.47%)

At close: Aug 14, 2025, 3:59 PM

8.46

-0.18%

After-hours: Aug 14, 2025, 07:56 PM EDT

-5.47% (1D)

Bid	8.02
Market Cap	2.56B
Revenue (ttm)	585.61M
Net Income (ttm)	96.55M
EPS (ttm)	0.37
PE Ratio (ttm)	22.91
Forward PE	11.92
Analyst	Buy

Ask	8.68
Volume	1,522,584
Avg. Volume (20D)	266,737
Open	8.85
Previous Close	8.96
Day's Range	7.81 - 8.85
52-Week Range	7.35 - 13.70
Beta	0.11

About ALVO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ALVO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ALVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Alvotech has released their quartely earnings on Aug 13, 2025:

Revenue of $173.24M exceeds estimates by $54.88M, with -12.83% YoY decline.

EPS of 0.14 exceeds estimates by 0.25, with -50.00% YoY decline.

Next Earnings Release

Alvotech is scheduled to release its earnings on Nov 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

+3.58%

Alvotech shares are trading higher after the compa... Unlock content with Pro Subscription

3 months ago

+18.14%

Alvotech shares are trading higher after the company reported better-than-expected Q1 financial results.

News

20 hours ago · seekingalpha.com

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

2 days ago · zacks.com

Alvotech (ALVO) Q2 Earnings and Revenues Beat Estimates

Alvotech (ALVO) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to earnings of $0.28 per share a year ago.

1 day ago · zacks.com

Wall Street Analysts Think Alvotech (ALVO) Could Surge 102.31%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 102.3% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the posi...

5 days ago · seekingalpha.com

Wall Street Week Ahead

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

2 weeks ago · zacks.com

Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect

ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.

3 weeks ago · zacks.com

Wall Street Analysts See a 91.05% Upside in Alvotech (ALVO): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 91.1% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the posit...

4 weeks ago · zacks.com

Down 6.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Alvotech (ALVO)

Alvotech (ALVO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

2 months ago · zacks.com

Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 72.6% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the posit...

2 months ago · benzinga.com

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

Alvotech ALVO on Thursday collaborated with Dr. Reddy's Laboratories Ltd. RDY to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.

2 months ago · zacks.com

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

Load More News